2026 Poster Presentations

Preliminary List as of September 3, 2026.

Alipheron AG
De-Risk Early Discovery. Expand Your IP Protection: Find Active Scaffolds via Exhaustive 2D & 3D Analogue Search in Commercial Trillion-Scale Spaces

Amgen, Inc.
Application of NanoBRET Technology for Hit Prioritization in a Protein-Protein Interaction Drug Discovery Program

Amgen, Inc.
Establishment of Spectral Shift Binder HTS Platform

Aragen Life Sciences
One Chemistry Platform, Multiple Modalities: Accelerating Drug Discovery Through Advanced Synthesis Technologies

Astex Pharmaceuticals
Discovery of ASTX295 - A Bone-Marrow Sparing MDM2 Antagonist: From Concept to Clinic

Atombeat, a DP Technology Company
PharmMaster: From Target Insight to Molecular Design

Atombeat, a DP Technology Company
Standardized Computational Services

Binghamton University, State University of New York
Next-Generation Immunosuppressive ADCs: Targeted Delivery of Glucocorticoids to Activated Immune Cells for Chronic Inflammation

Biortus Discovery, a Pharmaron Company
Structural Characterization of Protein Degraders via Cryo-EM and Crystallography

Biosensing Instrument
Surface Plasmon Resonance Microscopy Reveals Distinct Binding Kinetics of Small Molecules, Peptides, and Antibodies to GLP-1R on Whole Cells

Boston University
The Influence of Ligands on AlphaFold3 Prediction of Cryptic Pockets

BPS Bioscience, Inc.
Evaluating STAT6-Targeting Degraders Using Complementary Biochemical and Cell-Based Assays

Carterra, Inc.
High-Throughput SPR Screening and Kinetic Characterization Using Carterra Vega™ with AI Binding Prediction Comparison

Carterra, Inc.
Large-Scale Characterization of Drug Candidates Against Transmembrane Receptors Using HT-SPR

Case Western Reserve University
Structure-Based Repurposing of FDA-Approved Drugs Identifies Candidate Cereblon Modulators

Cayman Chemical Company
Validation and Characterization of Anti-Citrulline Antibodies and Citrullinated Proteins

Cell Origins
The Cell Surface Is the Epitope: Native-Context Discovery for Difficult Membrane Targets

CellarisBio
Assessing Cellular Target Engagement with MICRO-TAG®: ARID1B as an “Undruggable" Case Study

CellarisBio
Micro-Tag Cell Target Engagement Redefines GPCR Drug Discovery with Functional Relevance

Certara
Toward Canonical HELM Representations for Sequence-Level Peptide Registration

Chengdu Di'ao Pharmaceutical Co., Ltd.
Identification of Rapid-Acting, Orally Bioavailable Antidepressants via Selective Activation of TrkB Signaling

Clickmab Biotechnology
AI-Driven Platform for Function-Oriented De Novo Antibody Design

CNPEM - Brazilian Center for Research in Energy and Materials
Driving Radical Pharmaceutical Innovation in Brazil: The Integrated Drug Discovery Platform of LNBio/CNPEM

Concept Life Sciences
Development of a NEK7–NLRP3 Screening Cascade to Identify Potent, Selective Inhibitors for Neurological and Dermatological Disorders

Concept Life Sciences
Separating WEE1 from PLK1: Structure-Based Design of Selective WEE1 Inhibitors

Concept Life Sciences
Targeting NLRP3 Inflammasome Assembly: Discovery of Small-Molecule Inhibitors for Neurological and Inflammatory Diseases

Concept Life Sciences
Accelerating PROTAC Discovery Through a Direct-to-Biology Platform for Rapid BRD4 Degrader Identification

Confo Therapeutics
First Agonist Antibody Against a GPCR in Preclinical Development: CFTX-2034 for Post-Bariatric Hypoglycemia

Conigen Bioscience
Monoclonal Antibodies Against a Panel of GPCRs Can Detect the Targets Expressed on the Surface of Live Cells by Flow Cytometry

Conigen Bioscience
Unique Carrier-Free Immunization Can Generate Precision Antibodies Against High-Homology Short Peptide Targets

Cresset Biomolecular Discovery, Inc.
Accelerating Discovery of a METTL3 Inhibitor Through Efficient In Silico Design and Prioritization

Cube Biotech
From Copolymer Screening to Plug-and-Play Purification: Automated NativeMP™ Platforms for Membrane Proteins

Dalriada Drug Discovery
iCLASS: Live-Cell Drug Discovery Platform for Small Molecule Therapeutics Against the “Hard-to-Drug” Protein Targets

Diamond Light Source Ltd.
A Roadmap for Systematic Discovery of Novel Binding Pockets via Macromolecular Crystallography and QMMM

DIMA
The Application of Synthetic Nanodisc (Syndisc™) and PeptiNanodisc™ Technology Platforms to Develop Therapeutic mAbs for Multi-Pass Transmembrane Protein Targets

Domainex
Bringing Proteins Together: From Glue Identification to Mechanistic Understanding

Domainex
Building a Fragment-Based Drug Discovery Workflow for RNA Targets

Domainex
PureDisc: Unlocking Membrane Proteins for Structural Biology and Biophysics Utilising Native Membrane Polymer Nanodiscs

Edelris SAS
Molecular Glue Discovery Through Novel Chemical Space and AS-MS Screening

Edelris SAS
Unlocking the Unlockable: AS-MS for Swift Hit Identification Against Challenging Targets

EFS - French Blood Establishment / Mab Designs Ltd.
Antibodies Generated by Conformational Subtraction Differentiate Between Soluble and Membrane Bound Antigen

Ehime University
Target Deconvolution Using a 29,000-Human-Protein Array and AlphaScreen

Eli Lilly and Company
Development of a Novel Platform for Directed Protein Evolution

Eli Lilly and Company
Development of Novel Live Cell Based Screening Platform for GPCR-Stabilizing VHH Antibodies

Elucidata Corporation
Knowledge Graph Driven Insights and Drug Repurposing Opportunities for Neuroendocrine Prostate Cancer

EMD Serono, a business of Merck KGaA
Prime Editing to Create Near Pure Cysteine Mutant Cell Pools for Covalent Inhibitor Validation

Enamine
Discovery of Highly Potent BRD4 Degraders in a Series of Phenyl Dihydrouracil (PDHU) Derivatives

Eurofins Discovery
A Binder-First Discovery Platform for Kinase Molecular Glues Based on High-Throughput Spectral Shift Assays

Eurofins Discovery
Accelerating Tyrosine Kinase Inhibitor Drug Discovery with Selective Late-Stage Functionalization Strategies

Eurofins Discovery
Integrated High-Throughput Biochemical Binding and Cell-Based Targeted Protein Degradation Assay Platforms for STAT Degraders

Forge Biologics, a member of Ajinomoto Bio-Pharma Services
Unlocking the Full Potential of Antibody-Based Conjugates with AJICAP® Site-Specific Chemical Conjugation and Linker Technologies

GBI Biomanufacturing
Development of Antibody Conjugates via Site Directed Conjugation

Golgi
Variance-Modeled DIA Improves Quantitative Precision Across Global and Phosphoproteomic Workflows

HitChem
From Design to Application: A CRBN Molecular Glue Library Featuring Diverse and Unique CRBN Binders

ICE Bioscience
Hold-and-Kill: Validation Strategy of New RIPTAC Target Pairs

Immuto Scientific
Novel, Conformational Target Discovery in TKI-Resistant NSCLC

Institut Pasteur Korea
Development of Antiviral Drug via High-Throughput Screening and Phenotypic Image-Based AI Predictive Models

Inventia Life Science Pty Ltd
Developing 3D Cell Models for High-Throughput Antibody-Drug Conjugate Screening in Cancer

Jubilant Biosys
CDK4/6 PROTAC Degraders Design, Synthesis and Profiling

Korea Research Institute of Bioscience and Biotechnology
TXNIP Deficiency Exacerbates Experimental Colitis in Mice

Korea Research Institute of Chemical Technology
Pharmacological Targeting of Sirtuin 7(SIRT7) with a Novel Small-Molecule Inhibitor Suppresses Hepatocellular Carcinoma Growth

Kyoto University
Cell-Free Synthesis of Human Channel Proteins Enables Antibody Generation Against Challenging Channel Proteins

leadXpro AG
Enabling Structure Based Drug Discovery on Membrane Proteins

Lightcast Discovery Ltd.
Envisia: Advancing Antibody Discovery with Function-Focused Profiling at the Single-Cell Level

LiteFold, Inc.
LiteFold-Infrastructure for Precision Therapeutics

Massachusetts General Hospital
Small-Molecule Inhibitors of Nuclear Kinase ULK3 as a Strategy to Target Shared Epithelial–Stromal Regulatory Nodes for Skin Tumor Development and Field Cancerization

Mindstate Design Labs, Inc.
Pathway-Resolved Profiling Identifies Non-Canonical 5-HT7A/Gα15 Signaling by MSD-001 (5-MeO-MiPT)

Moffitt Cancer Center & Research Institute
Integrating Physics-Based Modeling and AI for Ligand Optimization

Molport
Peptide Macrocycles: A Global, Open-Access, In-Stock Resource for Challenging Drug Targets

Nuclera
From DNA to Active, Monomeric β1AR Receptor in <72 Hours

Nuvisan
Integrated Drug Discovery: Multiple Hit Identification Campaigns and Successful Hit-to-Lead Progression of Novel Inhibitors of Juno/Izumo1 Interaction

o2h
o2h's Integrated Phenotypic and Target-Based In Vitro Biology Platforms for Smarter, Faster Drug Discovery

ORIA Bioscience
A Medium-Throughput Organelle-Based Toolbox to Interrogate Diverse Drug Targets Across Therapeutic Areas

PAIA Biotech GmbH
Extensive Developability Profiling of a Diverse mAb Panel – From Biophysical Insight to PK Prediction

PAIA Biotech GmbH
pH-Dependent FcRn Binding and Release Assay in a Microplate: A New Method for Screening Fc Interactions of mAbs, Bispecifics and Fc Engineered Antibodies

PeptiFinder Biotech, Inc.
mRNA Display: Revolutionizing Drug Discovery

Perceptive, Inc.
A New Platform for Imaging Alpha Emitting Radiopharmaceuticals in Pre Clinical Cancer Models

Perceptive, Inc.
Bioequivalence and Dosimetry Estimates of GD2-Targeting Dinutuximab-Beta Labelled with Indium-111, Lutetium-177, and Actinium-225

PharmaBlock Sciences
ZoeStar™: A Building Block-Centered AI-Driven Drug Discovery Platform Integrating Chemical Space Exploration, Molecular Generation, and Lead Optimization

Pharmacelera
Driving Molecular Alignment with QM-Derived Descriptors to Analyse Kinase Selectivity Profiles

Pharmacelera
Optimization and Expansion of Fragment-Based Screening Libraries Through Reaction-Aware Virtual Design

Pharmagene Discovery Services
Exploring Functional Interactions In Situ Using a Combined Multiomic Approach

Pharmagene Discovery Services
Thorough Antibody Validation for Robust Spatial Biology Data

Pharmaron
Direct-to-Biology (D2B) Approach for Accelerated Targeted Protein Degrader Discovery

Pharos iBio Co., Ltd.
Proteomic Profiling Uncovers Synergistic Anti-Leukemic Efficacy of Lasmotinib and Menin Inhibitors in AML

Plex Research
A Fully Transparent and Automatable Focal Graph AI Platform for Biomarker and New Target Discovery Using Diverse Multi-Omics and Chemical Structure Data

Princeton High School
AI-Assisted Design of mTOR Inhibitors for Autism Spectrum Disorder

Promega Corporation
BRETSA: An Ultra-Sensitive, Broadly-Applicable BRET Method to Measure Target Engagement and Cellular Cooperativity Using Protein Denaturation

Promega Corporation
Lumit® Cell Proliferation Assay (Human Ki-67) with Optimized Performance for Screening Applications

Promega Corporation
Lumit-Based Profiling of Degrader Dynamics Reveals Signaling-Dependent, Cell Context-Specific Sensitivity to Degraders

Promega Corporation
Real-Time Monitoring of Targeted Protein Degradation in Living Cells: Enabling Live-Cell Kinetic Analysis at Every Step

Puerto Rico Science, Technology & Research Trust
A Proteome-Wide HuProt™ Microarray-Based Approach for Natural Product Target Identification

QUANTRO Therapeutics GmbH
From Undruggable to Actionable: Transcriptomic Discovery of Small-Molecule Modulators of Oncogenic Transcription Factors

Reaction Biology Corporation
A Comprehensive LinkLight Platform for GPCR Mechanistic Profiling to Support Cancer Drug Discovery

Reaction Biology Corporation
Evaluation of HUNK Inhibition by an FDA-Approved Drug as Potential Therapeutic Strategy for Aggressive Breast Cancer Subtypes

RG Discovery AB, part of Pelago Bioscience
Complex Structural Elucidation of Bicycle Drug Conjugate Zelenectide Pevedotin by NMR

Salipro Biotech AB
Stabilizing Challenging Membrane Proteins for Small-Molecule Drug Discovery with the Salipro Technology

Schrödinger, Inc.
A Rapid and Accurate Workflow to Classify Atropisomerism in Drug-Like Molecules

SEEDSUPPLY, INC.
Experimental Benchmarking Defines AI Applicability in SLCs

SpiroChem AG
SpiroQuest: Macrocycle Library, Novel Macrocycle Design and Virtual Library

Synfini, Inc.
The Agile Chemistry Foundry: Connecting Artificial Intelligence with Custom Robotic Synthesis to Accelerate Molecular Discovery

Takeda Pharmaceuticals U.S.A., Inc.
Optimizing Medium-Scale Protein Production Using Lynx Automation

Trailhead Biosystems
Development of a Robust Serum-Free Directed Differentiation Protocol for Functional hiPSC-Derived Endothelial Cells

Trilogie Bioscience
In Vitro Reconstituted Ubiquitylation Assays for Mechanistic Studies of Cullin-RING Ligases

Trilogie Bioscience
In Vitro Reconstituted Ubiquitylation Assays for Mechanistic Studies of E3 Ligases

Trince
Assessing Plate Consistency of LumiPore-Based Intracellular Delivery in Drug Screening

Unchained Labs
High-Throughput Protein Stability Screens with Aunty

University College Dublin
Discovering New Mechanism of Action to Drive New Therapeutic Development in T Cell-Mediated Diseases

University of Illinois at Chicago
Molecular Dynamics Simulations of Metabolite and Peptide Fibrils

University of Minnesota
Single Domain Antibodies Targeting the Third Intracellular Loop Are Receptor Subtype-Selective Allosteric Modulators

Vaccinex, Inc.
Antibody Discovery for Complex Membrane Antigens

Vazyme Biotech Co., Ltd.
Innovative Assays for Small Molecule Drug Screening

Vipergen ApS
DELs in Cells - Discovery of Small-Molecule Modulators of the Oncogenic Transcription Factor SOX2

WuXi AppTec
An Integrated Service Platform to Support the Discovery of Dual-Targeting Oligonucleotide Drugs to Treat Elevated ASCVD Risk in Diabetes

WuXi AppTec
Beyond Conventional HTS: Complementary Strategies for Discovering Modulators of Challenging Transcription Factors

WuXi AppTec
Spectral Shift Technology as Powerful Tool for Versatile Assay Applications in High-Throughput

WuXi AppTec
Synthetic-Lethality Screening with PARP1 Inhibition and Novel Non-CRBN Based Degrader Identification via High-Throughput Screen and Target Deconvolution by Proximity Labeling

WuXi XDC Co., Ltd.
Advancing AOC Development Through Linker Design and WuXiDARx™ DAR 1 Conjugation

X-Chem, Inc.
ReadiDEL: An Off-the Shelf DEL Platform that Accelerates Hit Discovery to Clinical Candidates

Yale University
Development of CORTACs as a Small Molecule Strategy to Enhance Degrader Specificity

Yale University
Integrative Chemical Genetics Platform Identifies Condensate Modulators Linked to Neurological Disorders

YUMAB GmbH
Next-Generation TCR-Like Antibodies with Improved Specificity Profiles

ZoBio
Biophysics-Driven Molecular Glue Discovery